Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01196390 · FLOW

Participant flow

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer · Source last updated 2026-06-02

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Radiation therapy with concurrent trastuzumab, paclitaxel, and carboplatin followed by surgery followed by maintenance trastuzumab
    id
    FG000
    title
    Chemoradiation and Trastuzumab
  2. description
    Radiation therapy with concurrent paclitaxel and carboplatin followed by surgery
    id
    FG001
    title
    Chemoradiation
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        4
      2. group Id
        FG001
        num Subjects
        5
      type
      Protocol Violation
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        102
      2. group Id
        FG001
        num Subjects
        101
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        98
      2. group Id
        FG001
        num Subjects
        96
      type
      Eligible
    3. achievements
      1. group Id
        FG000
        num Subjects
        95
      2. group Id
        FG001
        num Subjects
        96
      type
      Eligible and Started Study Treatment
    4. achievements
      1. group Id
        FG000
        num Subjects
        82
      2. group Id
        FG001
        num Subjects
        78
      type
      Eligible and Had Surgery
    5. achievements
      1. group Id
        FG000
        num Subjects
        88
      2. group Id
        FG001
        num Subjects
        83
      type
      Eligible and Consented to Quality of Life Component
    6. achievements
      1. group Id
        FG000
        num Subjects
        98
      2. group Id
        FG001
        num Subjects
        96
      comment
      Participants contributing data to results are considered to have completed the study
      type
      COMPLETED
    7. achievements
      1. group Id
        FG000
        num Subjects
        4
      2. group Id
        FG001
        num Subjects
        5
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
After registration, sites were required to submit participant tumor tissue for central human epidermal growth factor receptor 2 (HER2) testing. Only HER2-positive participants continued to randomization. In total, 571 participants were registered and 203 were randomized.
Complete source fields
groups
  1. description
    Radiation therapy with concurrent trastuzumab, paclitaxel, and carboplatin followed by surgery followed by maintenance trastuzumab
    id
    FG000
    title
    Chemoradiation and Trastuzumab
  2. description
    Radiation therapy with concurrent paclitaxel and carboplatin followed by surgery
    id
    FG001
    title
    Chemoradiation
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        4
      2. group Id
        FG001
        num Subjects
        5
      type
      Protocol Violation
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        102
      2. group Id
        FG001
        num Subjects
        101
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        98
      2. group Id
        FG001
        num Subjects
        96
      type
      Eligible
    3. achievements
      1. group Id
        FG000
        num Subjects
        95
      2. group Id
        FG001
        num Subjects
        96
      type
      Eligible and Started Study Treatment
    4. achievements
      1. group Id
        FG000
        num Subjects
        82
      2. group Id
        FG001
        num Subjects
        78
      type
      Eligible and Had Surgery
    5. achievements
      1. group Id
        FG000
        num Subjects
        88
      2. group Id
        FG001
        num Subjects
        83
      type
      Eligible and Consented to Quality of Life Component
    6. achievements
      1. group Id
        FG000
        num Subjects
        98
      2. group Id
        FG001
        num Subjects
        96
      comment
      Participants contributing data to results are considered to have completed the study
      type
      COMPLETED
    7. achievements
      1. group Id
        FG000
        num Subjects
        4
      2. group Id
        FG001
        num Subjects
        5
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
After registration, sites were required to submit participant tumor tissue for central human epidermal growth factor receptor 2 (HER2) testing. Only HER2-positive participants continued to randomization. In total, 571 participants were registered and 203 were randomized.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice